Roflumilast is the only phosphodiesterase 4 inhibitor approved for the treatment of COPD patients with chronic cough and sputum, and a history of exacerbations, but the compliance to treatment is reduced by poorly tolerated adverse events (AEs)
Abstract Background As chronic obstructive pulmonary disease (COPD) is a heterogeneous disease it is...
BACKGROUND: The phosphodiesterase-4 inhibitor roflumilast can improve lung function and prevent exac...
Lianfang Yuan,1 Xuan Dai,1 Meng Yang,2 Qiling Cai,1 Na Shao1 1Department of Respiration, Tianjin Ho...
Roflumilast is the only phosphodiesterase 4 inhibitor approved for the treatment of COPD patients wi...
Roflumilast is an oral phosphodiesterase-4 selective inhibitor with anti-inflammatory action targeti...
Background: Roflumilast, a phosphodiesterase 4 inhibitor, has been shown to improve lung function an...
Therapeutic interventions in chronic obstructive pulmonary disease (COPD) shown to reduce exacerbati...
IMPORTANCE OF THE FIELD: Chronic inflammation plays a central role in chronic obstructive pulmonary ...
After more than two decades of research into phosphodiesterase 4 (PDE4) inhibitors, roflumilast (3-c...
Background: Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease, which red...
The oral, selective phosphodiesterase type-4 inhibitor roflumilast reduces exacerbations and improve...
Selective phosphodiesterase (PDE) inhibitors are a class of nonsteroid anti-inflammatory drugs for t...
Background Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment...
Cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE)4 is an intracellular target that can b...
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) have few options for treatmen...
Abstract Background As chronic obstructive pulmonary disease (COPD) is a heterogeneous disease it is...
BACKGROUND: The phosphodiesterase-4 inhibitor roflumilast can improve lung function and prevent exac...
Lianfang Yuan,1 Xuan Dai,1 Meng Yang,2 Qiling Cai,1 Na Shao1 1Department of Respiration, Tianjin Ho...
Roflumilast is the only phosphodiesterase 4 inhibitor approved for the treatment of COPD patients wi...
Roflumilast is an oral phosphodiesterase-4 selective inhibitor with anti-inflammatory action targeti...
Background: Roflumilast, a phosphodiesterase 4 inhibitor, has been shown to improve lung function an...
Therapeutic interventions in chronic obstructive pulmonary disease (COPD) shown to reduce exacerbati...
IMPORTANCE OF THE FIELD: Chronic inflammation plays a central role in chronic obstructive pulmonary ...
After more than two decades of research into phosphodiesterase 4 (PDE4) inhibitors, roflumilast (3-c...
Background: Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease, which red...
The oral, selective phosphodiesterase type-4 inhibitor roflumilast reduces exacerbations and improve...
Selective phosphodiesterase (PDE) inhibitors are a class of nonsteroid anti-inflammatory drugs for t...
Background Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment...
Cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE)4 is an intracellular target that can b...
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) have few options for treatmen...
Abstract Background As chronic obstructive pulmonary disease (COPD) is a heterogeneous disease it is...
BACKGROUND: The phosphodiesterase-4 inhibitor roflumilast can improve lung function and prevent exac...
Lianfang Yuan,1 Xuan Dai,1 Meng Yang,2 Qiling Cai,1 Na Shao1 1Department of Respiration, Tianjin Ho...
DOI
Add to ORKG